<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862132</url>
  </required_header>
  <id_info>
    <org_study_id>VEDOKIDS</org_study_id>
    <nct_id>NCT02862132</nct_id>
  </id_info>
  <brief_title>Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases</brief_title>
  <official_title>Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases (IBD) Including Drug Levels: a Multi-center Prospective Cohort Study, From the Pediatric IBD Porto Group of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vedolizumab (VDZ) is a humanized immunoglobulin G1 monoclonal antibody acting against α4β7
      integrin which modulates lymphocyte trafficking in the gut.

      Results from the adult GEMINI-1 and GEMINI-2 trials demonstrated clinical efficacy in
      induction and maintenance of remission in both ulcerative colitis (UC) and Crohn's disease
      (CD), respectively.

      Recent real life cohorts in adults support the effectiveness of VDZ in inducing and
      maintaining remission, both in CD and UC. In pediatrics, there are very limited data on the
      use of VDZ besides two retrospective case series.

      Data on immunogenicity and therapeutic drug monitoring (TDM) of VDZ is conflicting in adults
      and practically non-existent in children.

      The investigators aim to prospectively explore the real life short and longer term outcomes
      of VDZ in pediatric IBD (including growth) and to develop a prediction model for treatment
      success based on VDZ trough levels and other clinical and laboratory variables.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center prospective cohort study in which the investigators are aim to enroll
      120 children under the age of 18 years, diagnosed with CD, inflammatory bowel disease
      unclassified (IBDU) or UC (approximately 60 in UC/IBDU and 60 in the CD group) who commenced
      on Vedolizumab for any reason at the discretion of the treating physician.

      Patients will be followed up to 3 years at 8 different time points: week 0, week 2, week 6,
      week 14, week 30, week 54 (1 year), week 108 (2 years) and week 162 (3 years). Blood work
      will be collected at each visit during the time of venous access insertion for the drug
      infusion for serum and stool sample will be collected at visits 0, 14, 30, and 54.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission at week 14</measure>
    <time_frame>weeks 14</time_frame>
    <description>As defined by all three criteria:
i. Steroids and Exclusive enteral nutrition (EEN) (defined as &gt;50% of daily calories with enteral nutrition)- free ii. Clinical remission (i.e. weighted Pediatric Crohn's Disease Activity Index (wPCDAI) &lt;12.5 points in CD, and Paediatric Ulcerative Colitis Activity Index (PUCAI) &lt;10 in UC) iii. CRP lower than 1.5 times upper normal limit (UNL) (may be substituted by Erythocytes Sedimentation Rate (ESR) if CRP missing)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission at week 30</measure>
    <time_frame>weeks 30</time_frame>
    <description>As defined by all three criteria:
i. Steroids and Exclusive enteral nutrition (EEN) (defined as &gt;50% of daily calories with enteral nutrition)- free ii. Clinical remission (i.e. weighted Pediatric Crohn's Disease Activity Index (wPCDAI) &lt;12.5 points in CD, and Paediatric Ulcerative Colitis Activity Index (PUCAI) &lt;10 in UC) iii. CRP lower than 1.5 times upper normal limit (UNL) (may be substituted by Erythocytes Sedimentation Rate (ESR) if CRP missing)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission at week 54</measure>
    <time_frame>weeks 54</time_frame>
    <description>As defined by all three criteria:
i. Steroids and Exclusive enteral nutrition (EEN) (defined as &gt;50% of daily calories with enteral nutrition)- free ii. Clinical remission (i.e. weighted Pediatric Crohn's Disease Activity Index (wPCDAI) &lt;12.5 points in CD, and Paediatric Ulcerative Colitis Activity Index (PUCAI) &lt;10 in UC) iii. CRP lower than 1.5 times upper normal limit (UNL) (may be substituted by Erythocytes Sedimentation Rate (ESR) if CRP missing)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission at week 108</measure>
    <time_frame>weeks 108</time_frame>
    <description>As defined by all three criteria:
i. Steroids and Exclusive enteral nutrition (EEN) (defined as &gt;50% of daily calories with enteral nutrition)- free ii. Clinical remission (i.e. weighted Pediatric Crohn's Disease Activity Index (wPCDAI) &lt;12.5 points in CD, and Paediatric Ulcerative Colitis Activity Index (PUCAI) &lt;10 in UC) iii. CRP lower than 1.5 times upper normal limit (UNL) (may be substituted by Erythocytes Sedimentation Rate (ESR) if CRP missing)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission at week 162</measure>
    <time_frame>weeks 162</time_frame>
    <description>As defined by all three criteria:
i. Steroids and Exclusive enteral nutrition (EEN) (defined as &gt;50% of daily calories with enteral nutrition)- free ii. Clinical remission (i.e. weighted Pediatric Crohn's Disease Activity Index (wPCDAI) &lt;12.5 points in CD, and Paediatric Ulcerative Colitis Activity Index (PUCAI) &lt;10 in UC) iii. CRP lower than 1.5 times upper normal limit (UNL) (may be substituted by Erythocytes Sedimentation Rate (ESR) if CRP missing)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steroid and EEN free clinical remission (without the need for normal CRP) using PCDAI or PUCAI score and concomitant medication list.</measure>
    <time_frame>week 30, week 54, week 108, week 162</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid and EEN free clinical response (without the need for normal CRP) using PCDAI or PUCAI score and concomitant medication list.</measure>
    <time_frame>week 30, week 54, week 108, week 162</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal calprotectin levels</measure>
    <time_frame>week 30, week 54, week 108, week 162</time_frame>
    <description>Levels of calprotectin will be measured in the lab using calprotectin kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum CRP levels</measure>
    <time_frame>week 30, week 54, week 108, week 162</time_frame>
    <description>CRP levels will be measured in the lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of loss of response including drug levels</measure>
    <time_frame>week 30, week 54, week 108, week 162</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid dependency (defined as cumulative use of &gt;4 months in a year with at least one need to increase dose while weaning)</measure>
    <time_frame>week 30, week 54, week 108, week 162</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>week 30, week 54, week 108, week 162</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of mucosal inflammation as available as part of clinical care using endoscopy, imaging or capsule endoscopy.</measure>
    <time_frame>week 30, week 54, week 108, week 162</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to induction of remission</measure>
    <time_frame>week 30, week 54, week 108, week 162</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal Physician Global Assessment (PGA)</measure>
    <time_frame>week 30, week 54, week 108, week 162</time_frame>
    <description>PGA will be measured using Visual analogue scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height velocity as compared with the year prior to commencing VDZ</measure>
    <time_frame>week 30, week 54, week 108, week 162</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for surgical interventions (including resections, colectomy, and dilatations)</measure>
    <time_frame>week 30, week 54, week 108, week 162</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Vedolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Vedolizumab 177mg/m2 Body Surface Area (BSA), max. 300mg Induction regimen: 0,2,6 and then every 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vedolizumab</intervention_name>
    <arm_group_label>Vedolizumab</arm_group_label>
    <other_name>Entyvio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children under the age of 18 years.

          2. IBD Diagnosis

          3. Initiating Vedolizumab therapy

        Exclusion Criteria:

        1. Starting Vedolizumab to prevent post operative recurrence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Turner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dana Marcus, Msc.</last_name>
    <phone>972-2-5645524</phone>
    <email>danam@szmc.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital for Children and Adolescents Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kaija-Leena Kolho, MD</last_name>
      <email>kaija-leena.kolho@helsinki.fi</email>
    </contact>
    <investigator>
      <last_name>Kaija-Leena Kolho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Our Lady's Children's Hospital Crumlin</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sadhbh O'Neill, PhD</last_name>
      <email>sadhbh.oneill@ncrc.ie</email>
    </contact>
    <investigator>
      <last_name>Seamus Hussy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Cener</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liat Pritzker</last_name>
      <email>liat.rambam@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ron Shaoul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadar Yehudai</last_name>
      <phone>+972-3-5028878</phone>
      <email>HADARY@wmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Arie Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Marcus, Msc.</last_name>
      <phone>972-2-5645524</phone>
      <email>danam@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Dan Turner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schneider Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadas Ozeri</last_name>
      <email>hadasoz@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Sara Hadas</last_name>
      <phone>972-3-9253039</phone>
      <email>hadassa@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Amit Assa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiri Lahav</last_name>
      <email>Shiri.Lahav@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Dror Shouval, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ichilov</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tal Gips</last_name>
      <email>talgi@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Shlomi Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh</name>
      <address>
        <city>Tzrifin</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilad Ben Yehuda</last_name>
      <email>Gastrolab@asaf.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Efrat Broide, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darja Urlep</last_name>
      <email>darja.urlep@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Darja Urlep, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Hospital for Children Glasgow</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Richmond, MD</last_name>
      <email>lisa.richmond@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Richard Russell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Slovenia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shaare Zedek Medical Center</investigator_affiliation>
    <investigator_full_name>Dr Dan Turner</investigator_full_name>
    <investigator_title>Head, The Juliet Keidan Institute of Pediatric Gastroenterology, Hepatology and Nutrition, Shaare Zedek Medical Center, Jerusalem, Israel</investigator_title>
  </responsible_party>
  <keyword>VDZ: Vedolizumab</keyword>
  <keyword>UC: Ulcerative colitis</keyword>
  <keyword>CD: Crohn's disease</keyword>
  <keyword>TDM: Therapeutic drug monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vedolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

